The discovery of molecular subtypes that predict treatment response represents a critical advance for precision cancer medicine. Bladder cancer patients have historically faced limited therapeutic options beyond standard chemotherapy, making biomarker-driven treatment selection increasingly vital for improving outcomes in this aggressive malignancy.
Analysis of 408 bladder cancer cases revealed that diminished levels of the regulatory RNA molecule hsa-miR-145-3p fundamentally alter tumor biology. Patients with low miR-145-3p expression showed significantly worse survival rates and more advanced disease characteristics, including increased lymph node involvement. The molecular mechanism involves this microRNA's control over multiple cancer-promoting genes, particularly ANO9, RAD54B, and SRSF6, which regulate cellular processes from DNA repair to protein synthesis. Loss of this regulatory control disrupts normal cell cycle checkpoints and enhances cancer cell survival.
Most significantly, miR-145-3p depletion transforms the immune landscape surrounding tumors. These cancers accumulate immunosuppressive cell types—including regulatory T cells and M2 macrophages—while depleting tumor-fighting CD8+ T cells and dendritic cells. This creates a hostile environment that actively protects cancer cells from immune attack. The research demonstrates that this immunosuppressive phenotype correlates with resistance to both standard platinum-based chemotherapy and emerging immunotherapy approaches, explaining why many patients fail to respond to current treatments.
However, the study identifies a therapeutic opportunity: tumors with low miR-145-3p expression show enhanced sensitivity to Dasatinib, a targeted kinase inhibitor. This finding suggests that molecular profiling for this microRNA could guide treatment decisions, directing patients toward therapies most likely to succeed based on their tumor's specific vulnerabilities rather than using one-size-fits-all approaches.